Stephen G. Machatha, Ph.D., serves as the Chief Development Officer at Aldeyra Therapeutics Inc., a biotechnology company focused on developing novel therapies for immune-mediated diseases. Dr. Machatha brings a wealth of experience in pharmaceutical development and regulatory affairs to his role, having spent over two decades in the industry. He holds a Ph.D. in Pharmaceutical Sciences from the University of Kansas and has held key positions at several leading pharmaceutical companies, including Bristol-Myers Squibb and Allergan. Throughout his career, Dr. Machatha has been instrumental in the development and successful regulatory approval of multiple drug candidates across various therapeutic areas. His expertise spans from early-stage drug discovery through to late-stage clinical development and commercialization. At Aldeyra Therapeutics, Dr. Machatha leads the company's development efforts, overseeing the clinical and regulatory strategies for their pipeline of innovative treatments. His leadership has been pivotal in advancing Aldeyra's lead product candidate, ADX-2191, through clinical trials and towards potential regulatory approval for the treatment of primary vitreoretinal lymphoma. In addition to his professional accomplishments, Dr. Machatha is an active member of several scientific and professional organizations, where he contributes to the advancement of pharmaceutical sciences and regulatory practices. His strategic vision and dedication to improving patient outcomes have made him a respected figure in the biotechnology industry, and his work at Aldeyra Therapeutics continues to drive the company's mission to develop transformative therapies for patients with unmet medical needs.